Clinical experience appears to show the benefit of SAMe and NR in individuals with a severe PRPS1 deficiency phenotype, or Arts syndrome, and we feel that these therapies in Arts syndrome patients should be considered. The gene discussed is PRPS1; the disease is Lethal ataxia with deafness and optic atrophy.